FDA Advisory Committee Recommends Approval of KALYDECO® (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation
U.S. Hot Stocks: Hot Stocks to Watch
Charting the October technical breakdown -- -2-
UPDATE: 11 stocks rising the most as the market heads toward a correction
Everything you need to know about investing you learned in grade school
Recent clinical success in cystic fibrosis positions Vertex as a dominant player in this attractive rare-disease market.
Following is a roundup of stocks that recently jumped to 5 stars in the last week. By way of background, we award a stock 5 stars when it trades at a suitably large discount--i.e., a margin of safety--to our fair value estimate. Thus, when a stock hits 5-star territory, we consider it an especially ...
We dive into the process for adding companies and booting them from the iconic index.
StockInvestor editor Matt Coffina and senior biotech analyst Karen Andersen discuss Gilead's growing competitive advantages.
On Thursday, Human Genome Sciences HGSI announced full positive Phase IIb Albuferon trial results from a study done on genotype 1 hepatitis C patients. We are maintaining our fair value estimate as we had already assigned a success rate for Albuferon equivalent to a Phase III drug when interim data ...